Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ANRS, Emerging Infectious Diseases
With
Merck Sharp & Dohme LLC
Antiretroviral treatment of HIV-1 Infection might interact with immunosuppressive treatments which increase rejection of renal graft incidence.
In addition HIV infection may be modified together with cardiovascular risk. Patients participating to this study will receive after transplantation antiretroviral regimen including Raltegravir.
Raltegravir treatment does not interact with immunosuppressive drugs and thus seems to be the treatment of choice to be associated with immunosuppressive drugs.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Registration on the French national renal transplantation waiting list (Biomedicines Agency) for a living or cadaveric donor organ
HIV-1-infected patients treated by a three-drug ARV regimen
Immuno-virologic criteria at renal transplantation: undetectable viral load (\<50 copies/mL) and CD4 \>200/mm3 for at least three months on stable ARV
Age \>18 years and \<70 years
Effective contraception for women
Written informed consent
Patient with social security coverage
You may not be if
Permanent:
* Hepatic cirrhosis
* Serious psychiatric illness history
* EBV or HHV8 lymphoproliferation (lymphoma, systemic Kaposi's sarcoma or multifocal Castleman's disease)
* History of PML
* HTLV-1 seropositivity
* Severe pulmonary or cardiovascular disease with poor short-term vital prognosis
* Patient with AgHBs+
* History of cryptosporidiosis
* History of fungal infection with multi resistant fungi not likely to respond to oral antifungal therapy
* Impossibility or refusal of Raltegravir switch, decision made by doctor or patient
Temporary:
* Recent malignancy (between 2 and 5 years according to type)
* HPV-related cervical or anal disease: carcinoma in situ, AIN III, CIN III in remission for less than three years
